Jounce Therapeutics
Edit info- Founded: 2013
- Location: Cambridge, MA
- Employee range: 101-250
- Funding: 100-500M
jouncetx.com linkedin.com job board
About:
Jounce Therapeutics is developing novel cancer immunotherapies that target the ICOS (Inducible Costimulatory Receptor) protein. ICOS is a cell surface receptor that is expressed on activated T cells. When ICOS binds to its ligand, ICOSL, it sends a signal that can either activate or suppress the T cell, depending on the context. In cancer, ICOS signaling can help to suppress the immune system's ability to attack tumor cells. Jounce Therapeutics is developing ICOS antagonists, which are drugs that block the interaction between ICOS and ICOSL. By blocking ICOS signaling, Jounce Therapeutics hopes to activate the immune system and help the body fight cancer.
Jobs:
News:
Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences - GlobeNewswire
googlenews
Mar 14, 2023
Funding-related
external-link
Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc - GlobeNewswire
googlenews
Apr 3, 2023
Science/business updates
external-link
Foresite Capital closes oversubscribed $668M venture fund
crunchbase
May 3, 2018
Funding-related
external-link
Bio Roundup: Trump News, Anthem’s Stand, Diversity by 2056 & More
crunchbase
Jan 27, 2017
Science/business updates
external-link
Celgene signs Jounce as its new biotech star in $2.6B ‘immuno-oncology 2.0’ pact - Endpoints News
googlenews
Jul 19, 2016
Funding-related
external-link
Jounce gets trounced as phase 2 data disappoint once again
fiercebiotech.com
Dec 23, 2024
Science/business updates
external-link
Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer - G
googlenews
Mar 16, 2023
Science/business updates
external-link
Gilead and Jounce Ink Potential $805 Million Immuno-Oncology Pact
crunchbase
Sep 1, 2020
Funding-related
external-link
Two years after PhII setback, Jounce’s lead I/O drug flops again despite biomarker approach - Endpoints News
googlenews
Aug 30, 2022
Science/business updates
external-link
Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced Cancers
crunchbase
Jun 2, 2018
Science/business updates
external-link
Jounce Therapeutics Founder Dr. James P. Allison Jointly - GlobeNewswire
googlenews
Oct 1, 2018
New hires
external-link
Jounce Therapeutics Appoints Robert Iannone, M.D., M.S.C.E., to its Board of Directors
crunchbase
Jan 23, 2020
New hires
external-link
Biotech makes surprise bid to snatch Jounce out of Redx's ...
fiercebiotech.com
Dec 23, 2024
Science/business updates
external-link
Jounce Acquisition: Exploring Whether It Is Worth It To Pay Up For CVR Value (NASDAQ:JNCE) - Seeking Alpha
googlenews
Apr 18, 2023
Science/business updates
external-link
Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
crunchbase
Mar 15, 2023
Funding-related
external-link
Jounce sinks as it ditches phase 2 Yervoy combo trial - Fierce Biotech
googlenews
Nov 3, 2020
Science/business updates
external-link
Celgene drops $2.6B Jounce pact, bags rights ...
fiercebiotech.com
Dec 23, 2024
Funding-related
external-link
Gilead deal reignites optimism in a cancer biotech - BioPharma Dive
googlenews
Sep 1, 2020
Science/business updates
external-link
Tang Capital’s Concentra offers $465M cash buyout of Lianbio - BioWorld Online
googlenews
Dec 4, 2023
Funding-related
external-link
Mysterious biotech makes last-minute bid to snatch Jounce out of Redx's hands - Fierce Biotech
googlenews
Mar 15, 2023
Science/business updates
external-link
Thinking about buying stock in Jounce Therapeutics, Kingsoft Cloud, Smartsheet, Oatly Group, or Deciphera Pharmaceuticals?
crunchbase
Mar 15, 2023
Funding-related
external-link
Tang Capital continues biotech buying spree with acquisition bid for Rain Oncology - Endpoints News
googlenews
Oct 16, 2023
Science/business updates
external-link
Redx to list on Nasdaq via merger with Jounce Therapeutics
crunchbase
Feb 23, 2023
Funding-related
external-link
Jounce Therapeutics to Announce Third Quarter 2020 - GlobeNewswire
googlenews
Oct 30, 2020
Science/business updates
external-link
Jounce jilts Redx for Concentra's surprise merger offer, plans to lay off 84% of workforce - Fierce Biotech
googlenews
Mar 27, 2023
Science/business updates
external-link
Are You Stable or Transient? Optimize Your Biotherapeutic Cell Line Workflows - Genetic Engineering & Biotechnology News
googlenews
Oct 5, 2020
Science/business updates
external-link
Jounce Therapeutics Reports First Quarter 2022 Financial Results
crunchbase
May 5, 2022
Funding-related
external-link
Gilead buys out rights to cancer therapy from Jounce for $67 mln - Reuters.com
googlenews
Dec 29, 2022
Funding-related
external-link
Need To Know: Analysts Are Much More Bullish On Jounce Therapeutics, Inc. (NASDAQ:JNCE)
crunchbase
Mar 1, 2021
Science/business updates
external-link
After Bristol snub, Gilead pens $120M upfront, $685M in biobucks for early Jounce cancer program - Fierce Biotech
googlenews
Sep 1, 2020
Funding-related
external-link
P/E Ratio Insights for Jounce Therapeutics
crunchbase
Sep 1, 2020
Science/business updates
external-link
Early Bird Rate Ending for What’s Hot in Cancer Immunotherapy 2017 on 6/14
crunchbase
Mar 22, 2017
Science/business updates
external-link
Chutes & Ladders—Aquestive CEO heads for the exits while seizure med remains in regulatory limbo - Fierce Biotech
googlenews
May 20, 2022
New hires
external-link
Gilead Sciences Places $120M Bet on a Jounce Therapeutics Cancer Drug
crunchbase
Sep 1, 2020
Funding-related
external-link
Jounce Therapeutics prices IPO beyond expectations (Updated)
crunchbase
Jan 27, 2017
Funding-related
external-link
Jounce to lay off half its workers, merge with UK biotech Redx - BioPharma Dive
googlenews
Feb 23, 2023
Science/business updates
external-link
Jounce jilts Redx for Concentra's surprise merger offer
fiercebiotech.com
Dec 23, 2024
Science/business updates
external-link
Jounce pounces on exit opportunity, laying off 57% of staff alongside reverse merger with Redx - Fierce Biotech
googlenews
Feb 23, 2023
Science/business updates
external-link
Jounce Therapeutics (JNCE) Stock: Why The Price Increased Over 15%
crunchbase
May 6, 2022
Science/business updates
external-link
Why The Jounce Therapeutics (JNCE) Stock Surged Over 40%
crunchbase
Dec 28, 2022
Science/business updates
external-link
Jounce Therapeutics Announces Restructuring - GlobeNewswire
googlenews
Feb 22, 2023
Science/business updates
external-link
Jounce tumbles as phase II NSCLC trial readout disappoints
crunchbase
Nov 2, 2020
Science/business updates
external-link
Concentra’s Buy Offer May Jeopardize Jounce’s Merger with Redx - BioSpace
googlenews
Mar 15, 2023
Science/business updates
external-link
Jounce setback casts deeper pall over ICOS as cancer target - pharmaphorum
googlenews
Aug 31, 2022
Science/business updates
external-link
Jounce Therapeutics to Present Two Posters from the JTX-4014 and Vopratelimab Programs at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting
crunchbase
Oct 1, 2019
Science/business updates
external-link
‘Like playing the lottery’: Laid-off life sciences workers give a snapshot of a cooling-down sector - The Boston Globe
googlenews
Oct 10, 2023
Science/business updates
external-link
Why Jounce Therapeutics Shares Are Trading Higher Today
crunchbase
Feb 23, 2023
Science/business updates
external-link
Why 2023 was the year of unsolicited acquisition bids — and why next year likely won’t be - Endpoints News
googlenews
Dec 20, 2023
Science/business updates
external-link
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics - Business Wire
googlenews
Dec 27, 2022
Science/business updates
external-link
Here's What We Learned About The CEO Pay At Jounce Therapeutics, Inc. (NASDAQ:JNCE) - Yahoo Finance
googlenews
Sep 11, 2020
Science/business updates
external-link
Should You Avoid Jounce Therapeutics, Inc. (JNCE)?
crunchbase
Jul 5, 2020
Science/business updates
external-link
Jounce Therapeutics Secures $56 Million in ...
fiercebiotech.com
Dec 23, 2024
Funding-related
external-link
Stocks to Watch: eBay, Etsy, Jounce Therapeutics, Dutch Bros, Cheesecake Factory
crunchbase
Feb 22, 2023
Science/business updates
external-link
Hunting for cash, Jounce sells remaining stake in tumor antibody to partner Gilead for $67M - Fierce Biotech
googlenews
Jan 3, 2023
Funding-related
external-link
Jounce Therapeutics soars as Gilead amends immunotherapy deal
crunchbase
Dec 28, 2022
Science/business updates
external-link
Celgene licenses antibody JTX-8064 from Jounce for $50m - Pharmaceutical Technology
googlenews
Jul 24, 2019
Funding-related
external-link
Jounce plunges after ASCO abstract reveal
crunchbase
May 17, 2018
Science/business updates
external-link
Jounce Gets $102M As Biotech IPOs Gain Steam in ’17
crunchbase
Jan 27, 2017
Funding-related
external-link
Jounce Therapeutics Stock Gets A $5 Price Target (JNCE)
crunchbase
Jan 13, 2023
Science/business updates
external-link
Concentra makes bid for struggling biotech Rain - BioPharma Dive
googlenews
Oct 16, 2023
Funding-related
external-link
A startup trying to get the human body to fight cancer just filed for an IPO
crunchbase
Jan 4, 2017
Funding-related
external-link
Jounce Therapeutics stock bounces after saying only 1.4% of its cash was in an SVB operating account
crunchbase
Mar 13, 2023
Funding-related
external-link
In the midst of a reverse merger, Jounce Therapeutics gets competing offer
crunchbase
Mar 15, 2023
Funding-related
external-link
Jounce lays off 57% of staff, agrees reverse merger with ...
fiercebiotech.com
Dec 23, 2024
Science/business updates
external-link
Jounce Therapeutics earns clinical milestone payment under the CCR8 exclusive license agreement with Gilead Sciences, Inc.
crunchbase
Nov 2, 2022
Funding-related
external-link
Jounce gets trounced as phase 2 data disappoint once again, prompting pipeline rethink - Fierce Biotech
googlenews
Aug 31, 2022
Science/business updates
external-link
Jounce sells remaining stake in antibody to Gilead for $67M
fiercebiotech.com
Dec 23, 2024
Funding-related
external-link
Jounce Therapeutics Announces Closing of Tender Offer - GlobeNewswire
googlenews
May 3, 2023
Funding-related
external-link
Jounce Therapeutics Enters Into Agreement to Be Acquired by - GlobeNewswire
googlenews
Mar 27, 2023
Science/business updates
external-link
Jounce Therapeutics Shares Up 12% After Hours On Layoff Plans
crunchbase
Feb 22, 2023
Science/business updates
external-link
The Punching Bag of Biotech Absorbs More Blows
crunchbase
May 17, 2018
Science/business updates
external-link
UPDATE 1-Biotech firms Redx Pharma and Jounce Therapeutics to merge in $425 mln deal
crunchbase
Feb 23, 2023
Funding-related
external-link
Visterra, Braeburn Stumble After Solid ’17 Start for Bio IPOs
crunchbase
Feb 10, 2017
Science/business updates
external-link
Jounce Therapeutics Reports Second Quarter 2021 Financial Results
crunchbase
Aug 5, 2021
Science/business updates
external-link
Xaira Therapeutics Appoints Dr. Debbie Law as Chief Scientific Officer and Julia Tran as Chief People Officer - Business Wire
googlenews
Oct 17, 2024
New hires
external-link
Celgene drops $2.6B Jounce pact, bags rights to macrophage drug - Fierce Biotech
googlenews
Jul 24, 2019
Funding-related
external-link
Jounce sinks as it ditches phase 2 Yervoy combo trial
fiercebiotech.com
Dec 23, 2024
Science/business updates
external-link
New chapter in Theseus’ adventure as troubled biotech approached by two potential suitors - Fierce Biotech
googlenews
Nov 27, 2023
Science/business updates
external-link
Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors
crunchbase
Sep 15, 2021
New hires
external-link
© 2025 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com